HIGHLIGHTS
- who: Michael Kreuter from the Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik, Heidelberg University Hospital, Röntgenstraße, Heidelberg, Germany have published the Article: Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials, in the Journal: (JOURNAL)
- what: The aim of this analysis was to evaluate change in HRQoL and symptoms from baseline to week 52 in three subgroups defined by absolute decline in FVC % predicted over the study period. It should also be noted that the key HRQoL . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.